Abciximab (Reopro, Abcixifiban): Difference between revisions

From Anesthesia Wiki
Jump to navigation Jump to search
No edit summary
Tags: Replaced Manual revert
 
Line 3: Line 3:
[[Category:Anticoagulant]]
[[Category:Anticoagulant]]
[[Category:Glycoprotein IIb/IIIa inhibitors]]
[[Category:Glycoprotein IIb/IIIa inhibitors]]
'''Abciximab (Reopro, Abcixifiban)'''
Abciximab, sold under the brand names Reopro and Abcixifiban, is a medication used to prevent blood clots in people undergoing coronary angioplasty. It is a glycoprotein IIb/IIIa inhibitor, which means that it blocks the platelets in the blood from aggregating and forming clots. This medication is administered intravenously during the procedure, usually in combination with heparin and aspirin.
==Mechanism of action==
Abciximab blocks the glycoprotein IIb/IIIa receptor on the surface of platelets, preventing the binding of fibrinogen and other ligands that are necessary for platelet aggregation and clot formation.
==Indications==
Abciximab is primarily used to prevent blood clots during cardiovascular procedures, such as:
    Coronary angioplasty
    Coronary artery bypass surgery
    Stent placement
It may also be used in other situations where the risk of blood clots is high.
==Required laboratory tests==
Before administering abciximab, healthcare providers may order laboratory tests to assess the patient's blood clotting function, including:
    Platelet count
    Prothrombin time (PT)
    Activated partial thromboplastin time (aPTT)
    International normalized ratio (INR)
==Dosing for every route of administration==
The dosing of abciximab varies depending on the indication and the patient's weight. It is administered intravenously during the procedure.
For coronary angioplasty, the typical dosing regimen is:
    A bolus of 0.25 mg/kg over 1-2 minutes
    A maintenance infusion of 0.125 μg/kg/min for 12 hours
For coronary artery bypass surgery, the typical dosing regimen is:
    A bolus of 0.25 mg/kg over 1-2 minutes
    A maintenance infusion of 0.125 μg/kg/min for up to 24 hours
For stent placement, the typical dosing regimen is:
    A bolus of 0.25 mg/kg over 1-2 minutes
    A maintenance infusion of 10 μg/min for up to 12 hours
==Adverse reactions==
Some common adverse reactions associated with abciximab include:
    Bleeding
    Bruising
    Low blood pressure
In rare cases, it can cause severe allergic reactions or blood clotting disorders, such as:
    Thrombocytopenia
    Thrombosis
    Hemorrhage
==References==
{{Reflist}}
==External links==
    [https://www.anesthesia.wiki/index.php/Abciximab_(Reopro,_Abcixifiban) Abciximab page on the Anesthesia Wiki]
{{Pharmaceutical-drug-stub}}

Latest revision as of 18:46, 9 May 2023

Retrieved from "https://www.anesthesia.wiki/index.php?title=Abciximab_(Reopro,_Abcixifiban)&oldid=1730"